Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2019

View Archived Issues

AQAMAN: Heroic inhibitor restrains polyQ aggregation

Gilead presents first data for anti-HIV antibody GS-9722

Beijing Xuanyi Pharmasciences patents CDK4 and CDK6 inhibitors

Istituto Europeo di Oncologia discloses new KDM1A inhibitors

STING innate immune protein induces autophagy

Innate immune signaling complexes are multifunctional, programmable

Agios Pharmaceuticals synthesizes PKM activators

PROLONG study of Makena does not meet coprimary endpoints

GlaxoSmithKline identifies new compounds for tuberculosis

Saint Louis University discloses ESRRG inverse agonists

Interim phase I data reported for GS-6207

GlaxoSmithKline's GSK-2838232 shows activity in phase IIa study in patients with HIV

Discovery of new TRPV4 agonist as regulators of chondrogenic differentiation

Saniona initiates phase IIa study of Tesomet for hypothalamic obesity

FDA grants accelerated approval to Tecentriq plus chemotherapy in PD-L1-positive metastatic TNBC

Pharmacokinetic data on VRC-01 LS in HIV-exposed newborns reported

Topline results from first-in-human study of TLC-590 for postsurgical pain

Dicerna enrolling in phase II study of DCR-PHXC for primary hyperoxaluria

MGB Biopharma studies MGB-BP-3 for C. difficile-associated diarrhea in new phase IIa trial

UCL initiates phase I/II study of MSCTRAIL in metastatic NSCLC

ProQR initiates first-in-human study of QR-421a for Usher's syndrome type 2

FDA clears Rubius' IND application for phase Ib trial of RTX-134 for PKU